X

Trial Profile

Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inodiftagene-vixteplasmid (Primary) ; Inodiftagene-vixteplasmid (Primary) ; BCG; BCG
Indications Bladder cancer; Carcinoma
Focus Adverse reactions
Sponsors Anchiano Therapeutics; BioCancell Therapeutics

Most Recent Events

10 Mar 2018 Status changed from recruiting to completed, according to the results presented at the 2018 Genitourinary Cancers Symposium.
10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium
01 Oct 2015 Results published in BioCancell media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com